Preventing Infection Proactively

Sudhakar Singh, Managing Editor

As an after-effect of Covid-19 pandemic, there is an increased pressure to ensure the safety of both patients and frontline healthcare workers from hospital acquired infections. This has given a boost to the growth of sterile products market. In this issue, we have focused on this niche segment. The cover story of this issue features Inject Care Parenterals which is a manufacturing company that provides complete sterile manufacturing solutions to its clients. Having served as a reputable enterprise in the field of dry powder Beta-lactum and Cephalosporin Injectables, Inject Care Parenterals Pvt, Ltd is rightfully a pioneer in this field. It is one of the select few dedicated high-volume production capacity units in India. It is one of the most preferred businesses in the contract manufacturing space that manufactures Beta Lactam Dry Powder Injectables in a specialized facility. With a monthly production capacity of 12 million vials in a single shift, Inject Care flourishes on large-scale production of the goods. Also featuring in the issue is Celon Labs which is India's leading specialty biopharmaceutical company at the forefront of research, manufacturing, and marketing of high quality formulations in niche therapy areas of Oncology and Critical Care. Its expertise in novel technology platforms enables in-house development of potential molecules used in Critical Care and complies with Indian and international regulatory requirements through an Integrated approach toward quality control, quality assurance, and production.

Keeping tabs on this market, we have shortlisted the top 10 companies that have exhibited an unrelenting pursuit of excellence. By proving their dedication to fulfilling customer expectations and contributing to the market’s evolution through their innovative disposition, these companies are blazing a trail for others to follow and setting an example for them.

We look forward to receiving your feedback and suggestions.

© 2024 India Pharma Outlook. All Rights Reserved.